Adverse events of targeted therapies

Current Opinion in Oncology

Volumn 26, Issue 4, 2014, Pages 395-402

  Klastersky, Jean A ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adverse events; Cancer treatment; Supportive care; Targeted therapies

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; ECULIZUMAB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; OLAPARIB; PANITUMUMAB; PAZOPANIB; PEMBROLIZUMAB; PERTUZUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TIVOZANIB; TRASTUZUMAB; VANDETANIB; VEMURAFENIB; VISMODEGIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ADVERSE DRUG REACTION; ANOREXIA; ARTHRALGIA; ASTHENIA; ASTHMA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLEPHARITIS; BRONCHIOLITIS; CANCER CHEMOTHERAPY; CANCER PATIENT; COMORBIDITY; CONJUNCTIVITIS; CORNEA ULCER; DIARRHEA; DISEASE SEVERITY; DYSPEPSIA; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INFECTION; INTERSTITIAL PNEUMONIA; JAW OSTEONECROSIS; KERATITIS; LUNG EMBOLISM; LUNG TOXICITY; MUCOSA INFLAMMATION; MUSCLE SPASM; MYALGIA; NAUSEA; PLEURA EFFUSION; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOEMBOLISM; THROMBOPHLEBITIS; VENOUS THROMBOEMBOLISM; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; WOUND HEALING IMPAIRMENT; XEROPHTHALMIA; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84902281627     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000096     Document Type: Review

References (34)

1. Roth BJ, Krilov L, Adals S, et al. Clinical cancer advances 2012: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2013; 31:131-161.
2. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
3. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as secondline treatment for advanced renal cell carcinoma; overall survival analysis and updated results from a randomized phase 3 trial. Lancet Oncol 2013; 14:552-562.
4. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722-731.
5. Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 2012; 18:6023-6031.
6. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012; 30:1678-1685.
7. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31:412-419.
8. Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 2013; 49:3412-3419.
9. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134-141.
10. Jonker DJ, OCallaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-2048.
11. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-Associated cardiac effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-3865.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
13. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomized controlled trial. Lancet Oncol 2011; 11:236-244.
14. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-1664.
15. Gianni L, Llado A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:1131-1137.
16. Blackwell K, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab- refractory metastatic breast cancer. J Clin Oncol 2010; 28:1124-1130.
17. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538-5546.
18. Yoshida T, Yamada K, Azuma K, et al. Comparison of adverse events and efficacy between gefinitib and erlotinib in patients with nonsmall-cell lung cancer: A retrospective analysis. Med Oncol 2013; 30:349.
19. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-2394.
20. Kwak EL, Bang YJ, Camidge R, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
21. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382-1392.
22. Yoo C, Ryu MH, Ryoo BY, et al. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors. Invest New Drugs 2013; 31:1367-1374.
23. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
24. Sekulic A, Midgen MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366:2171-2179.
25. Paplomata E, Zelnak A, ORegan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat 2013; 140:453-462.
26. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
27. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.
28. Issacs D. Infectious risks associated with biologics. Adv Exp Med Biol 2013; 764:151-158.
29. Lee CC, Ho HC, Hsiao SH, et al. Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis. PLos One 2012; 7:e50163.
30. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-4274.
31. Rafailidis PI, Kakisi OK, Vardakas K, et al. Infectious complications of monoclonal antibodies used in cancer therapy. Cancer 2007; 109:2182-2189
32. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-119.
33. Narita Y. Drug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin Oncol 2013; 43:587-595.
34. Dai F, Shu L, Bian Y, et al. Safety of bevacizumab in treating metastatic colorectal cancer: A systematic review and meta-Analysis of all randomized clinical trials. Clin Drug Investig 2013; 33:779-788.